Calquence

Description

Calquence is a new generation medicine developed for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma in adult patients who have had at least one course of treatment behind them. The basis of the drug is the active substance Acalabrutinib, which is an inhibitor of Bruton’s tyrosine kinase. As a result of its entry into the patient’s body, the survival of malignant lymphocytes and tumor growth are suppressed.

Active ingredient: acalabrutinib

Prescription medicine